Lexeo Therapeutics (LXEO) Research & Development (2022 - 2026)

Lexeo Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• In Q1 2026, Research & Development fell 8.55% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $46.1 million (down 38.93% YoY), while the FY2025 annual figure was $63.8 million, down 13.89% from the prior year.
• Research & Development came in at $15.7 million for Q1 2026 at Lexeo Therapeutics, roughly flat from $15.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $23.4 million in Q3 2024 to a low of -$44.9 million in Q4 2023.
• A 5-year average of $11.7 million and a median of $15.7 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development plunged 494.48% in 2023 and soared 140.89% in 2024, its largest moves.
• Lexeo Therapeutics' Research & Development stood at $11.4 million in 2022, then slumped by 494.48% to -$44.9 million in 2023, then jumped by 140.89% to $18.4 million in 2024, then decreased by 14.54% to $15.7 million in 2025, then rose by 0.05% to $15.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.7 million, $15.7 million, and $14.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison